Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Mochi and Hims dominate the telehealth GLP-1 space, each serving millions of patients seeking convenient weight management and metabolic support. Both platforms offer rapid consultations and direct-to-consumer medication delivery, yet they differ significantly in medication sourcing, pricing models, and clinical oversight structures.

Choosing between Mochi and Hims—or exploring alternatives like compounded formulations—becomes clearer when you understand your genetic predispositions in GLP-1 and GIPR pathways. Genetic testing that reveals these peptide-specific variants may help providers customize dose escalation, product selection, and monitoring strategies for better outcomes.

Understanding Mochi's Telehealth Model and GLP-1 Offerings

Mochi is a direct-to-consumer telehealth platform launched to streamline GLP-1 access through simplified, affordable consultations. The company partners with healthcare providers to prescribe semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), primarily sourcing branded medications from pharmaceutical manufacturers.

Mochi's business model emphasizes low-cost initial consultations ($0–$30), with ongoing medication costs dependent on insurance coverage and pharmacy selection. The platform targets price-sensitive patients and those seeking simplified entry into GLP-1 therapy without extensive medical history reviews.

Hims' Integrated Telehealth and Pharmacy Infrastructure

Hims operates a vertically integrated telehealth-to-pharmacy ecosystem, meaning consultations and medication dispensing occur within one company. Hims offers semaglutide, tirzepatide, and other GLP-1 options, with pricing starting around $199/month for compounded formulations and higher rates for branded products.

Hims differentiates through in-house pharmacy services, allowing tighter clinical oversight and faster medication adjustments. The platform includes broader health services (ED, hair loss, mental health), positioning GLP-1 within a comprehensive wellness narrative rather than as an isolated weight-loss tool.

Mochi vs Hims: Clinical and Operational Comparison

Both platforms employ licensed physicians for prescribing, yet their clinical depth and personalization strategies differ markedly. Mochi prioritizes speed and affordability; Hims invests in integrated data systems that connect consultation, dispensing, and outcome tracking. Neither platform currently incorporates genetic testing into standard workflows, though this practice is emerging in precision-wellness medicine.

Criteria Mochi Hims PlexusDx Compounded Model
Medication Source Primarily branded (Ozempic, Mounjaro) Branded + compounded options Licensed 503A compounded only
Initial Consultation $0–$30 $99–$199 per visit Varies by provider partner
Ongoing Monthly Cost $129-$369/mo+ (branded) $199–$500+ (varies) $129–$309 (compounded)
Genetic Testing Offered Not standard Not standard Precision Peptide Genetic Test ($99 add-on)
Pharmacy Model Partner pharmacies In-house pharmacy Licensed 503A compounders
Clinical Oversight Physician-led, minimal follow-up Physician-led, integrated tracking Provider-directed personalization

Why Genetic Testing Matters in GLP-1 Selection

Variants in GLP1R, GIPR, FTO, and MC4R genes influence how individuals respond to GLP-1 therapy, weight loss patterns, and medication tolerance. Understanding these predispositions may help providers select appropriate starting doses, anticipate side effect profiles, and adjust protocols faster than trial-and-error approaches.

Genetic insights do not predict exact medication response but provide context for clinical decision-making. A patient with specific GIPR or GLP1R variants may benefit from dual-agonist formulations (like tirzepatide) or microdose protocols, whereas standard escalation schedules might not optimize outcomes for their biology.

Comparing Mochi, Hims, and Precision-Informed Compounded Alternatives

Mochi and Hims serve different patient profiles: Mochi appeals to those prioritizing cost and simplicity, while Hims attracts patients seeking integrated clinical support. Neither platform emphasizes genetic personalization, leaving a gap for patients wanting biology-informed dosing and formulation selection.

PlexusDx compounded GLP-1 options paired with Precision Peptide Genetic Testing offer a third pathway. This model targets patients willing to invest in genetic insights and compounded flexibility, receiving medications manufactured in licensed 503A pharmacies (not 503B mass-production facilities) with provider-guided personalization.

Safety, Eligibility, and Medical Oversight Considerations

Mochi and Hims both require basic medical screening, but neither mandates extensive metabolic profiling, blood work, or genetic assessment. Patients with complex medical histories, concurrent medications, or metabolic disorders should undergo thorough evaluation before starting any GLP-1 regimen, regardless of platform.

Compounded GLP-1 medications carry the same clinical benefits and risks as branded versions, though sourcing from licensed 503A pharmacies ensures pharmacy-level quality oversight. Patients choosing any GLP-1 therapy should expect regular follow-up consultations, weight monitoring, and dose adjustments under qualified healthcare provider supervision.

How PlexusDx Supports a More Personalized Approach

Genetic testing that reveals predispositions in GLP-1 and GIPR pathways may help providers tailor medication selection and dosing strategies to individual biology. The Precision Peptide Genetic Test examines variants like GLP1R rs6923761 and GIPR rs1800437, providing context—not guarantees—for personalized treatment conversations.

PlexusDx partners with licensed 503A compounding pharmacies to offer customized semaglutide and tirzepatide formulations starting at $149/mo per month. When paired with Precision Peptide Genetic Testing ($99 add-on), this approach supports more informed clinical decisions compared to standard telehealth workflows without genetic insight.

Unlike mass-manufactured 503B products, compounded medications from PlexusDx-partner pharmacies allow dose flexibility and formulation adjustments based on clinical response and genetic context. This personalization pathway is ideal for patients seeking provider-guided precision wellness aligned with their peptide pathway biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Mochi and Hims GLP-1 programs?

Mochi prioritizes low-cost, rapid consultations with branded medication sourcing, while Hims offers integrated telehealth-pharmacy infrastructure with both branded and compounded options, enabling more comprehensive clinical tracking and personalization.

Does Mochi or Hims offer genetic testing before GLP-1 selection?

Neither Mochi nor Hims includes genetic testing in standard workflows. PlexusDx offers Precision Peptide Genetic Testing ($99 add-on) to reveal GLP-1 and GIPR pathway predispositions, supporting more informed medication and dosing choices with qualified providers.

Which platform costs less: Mochi or Hims?

Mochi's initial consultation is $0–$30 with medication costs $129-$369/mo+ monthly (branded). Hims consultations start at $99–$199 with monthly costs $199–$500+. PlexusDx compounded options range $129–$309 monthly, potentially lower than branded alternatives through insurance or direct pay.

Are compounded GLP-1 medications from PlexusDx as safe as Mochi or Hims options?

Compounded semaglutide and tirzepatide from licensed 503A pharmacies carry identical clinical mechanisms and safety profiles as branded versions. PlexusDx medications are compounded under strict pharmacy oversight; all require qualified healthcare provider supervision and regular monitoring.

How can genetic testing help me choose between GLP-1 platforms or medication types?

Genetic variants in GLP1R, GIPR, FTO, and MC4R influence dose response and weight loss patterns. Precision Peptide Genetic Testing may help providers recommend appropriate starting doses, dual-agonist formulations, or microdose protocols tailored to your peptide pathway biology—supporting more personalized outcomes.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves